We are live on !
Find out more
Ally Bridge Group Portfolio holdings
AUM
$113M
Turnover
66.67%
1-Year Est. Return
245.92%
This Fund
S&P 500
This Quarter Est. Return
+16.04%
1 Year Est. Return
+245.92%
3 Year Est. Return
+843.68%
5 Year Est. Return
+787.29%
10 Year Est. Return
–
AUM
$113M
AUM Growth
-$10.7M
(-8.7%)
Cap. Flow
-$30.4M
Cap. Flow % of AUM
Cap. Flow %
-26.9%
Top 10 Holdings %
Top 10 Hldgs %
70.48%
Holding
39
New
12
Increased
2
Reduced
9
Closed
14
Avg Time Held
Equity + Options
0.4
years
Top 10 Avg Time Held
Equity + Options
0.1
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.4
years
Top 10 Avg Time Held Equity only
0.1
years
Top 20 Avg Time Held Equity only
0.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$5.31M |
| 2 |
Assembly Biosciences
ASMB
|
+$3.81M |
| 3 |
Axsome Therapeutics
AXSM
|
+$3.58M |
| 4 |
Minerva Neurosciences
NERV
|
+$2.82M |
| 5 |
Kura Oncology
KURA
|
+$2.74M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$10.6M |
| 2 |
Soleno Therapeutics
SLNO
|
+$6.7M |
| 3 |
Compass Pathways
CMPS
|
+$5.78M |
| 4 |
Tarsus Pharmaceuticals
TARS
|
+$5.67M |
| 5 |
Ovid Therapeutics
OVID
|
+$5.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.63% |
| 2 | Miscellaneous | 31.37% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Abivax
ABVX
$7.87B
| – | – |
-33,712
| Closed | -$3.82M | – |
|
27
Capricor Therapeutics
CAPR
$356M
| – | – |
-113,899
| Closed | -$3.46M | – |
|
28
CALL
Compass Therapeutics
CMPX
$144M
| – | – |
-1,000,000
| Closed | -$5.29M | – |
|
|
29
Compass Pathways
CMPS
$1.61B
| – | – |
-1,045,000
| Closed | -$5.78M | – |
|
30
Inhibikase Therapeutics
IKT
$227M
| – | – |
-1,325,000
| Closed | -$2.23M | – |
|
31
CALL
Karyopharm Therapeutics
KPTI
$12.4M
| – | – |
-250,000
| Closed | -$1.39M | – |
|
|
32
Praxis Precision Medicines
PRAX
$7.23B
| – | – |
-32,810
| Closed | -$10.6M | – |
|
33
CALL
uniQure
QURE
$1.6B
| – | – |
-300,000
| Closed | -$4.9M | – |
|
34
CALL
Replimune Group
REPL
$1.13B
| – | – |
-246,900
| Closed | -$1.89M | – |
|
35
Relmada Therapeutics
RLMD
$351M
| – | – |
-210,525
| Closed | -$1.47M | – |
|
|
36
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-200,000
| Closed | -$6.7M | – |
|
|
37
PUT
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-200,000
| Closed | -$6.7M | – |
|
|
38
Tarsus Pharmaceuticals
TARS
$3.37B
| – | – |
-80,859
| Closed | -$5.67M | – |
|
39
CALL
Maze Therapeutics
MAZE
$1.77B
| – | – |
-100,000
| Closed | -$2.98M | – |
|
Similar funds
TWS
Ally Bridge Group's Q2 2026 Portfolio in Review
As of Q2 2026, Ally Bridge Group held 39 positions worth $113M, down 8.7% from $124M the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Ally Bridge Group withdrew a net $30.4M in Q2 2026, closing 14 positions and reducing 9 holdings. Its most notable exit was Praxis Precision Medicines, an estimated $10.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 81% a quarter earlier, followed by Miscellaneous.
Against the trend, Ally Bridge Group opened a new position in First Tracks Biotherapeutics worth $5.72M.
- Ally Bridge Group's largest Q2 2026 buy was First Tracks Biotherapeutics: 284,287 shares worth $5.72M.
- Ally Bridge Group added most to Minerva Neurosciences in Q2 2026, an estimated $2.82M increase.
- Ally Bridge Group's biggest Q2 2026 reduction was Ovid Therapeutics, cutting an estimated $5.66M.
- Ally Bridge Group fully exited Praxis Precision Medicines in Q2 2026, selling an estimated $10.6M.
- Ally Bridge Group's ten largest holdings make up 70% of its $113M portfolio in Q2 2026.
- Ally Bridge Group opened 12 new positions and closed 14 in Q2 2026.
- Ally Bridge Group's portfolio value fell 8.7% quarter-over-quarter to $113M.
Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.